Challenges for foreign pharma companies in relation to Indonesia’s pharma system include lengthy and variable approval periods, compulsory licenses, and counterfeits. Furthermore, drug companies are not allowed to have a foreign investment level of more than 75%.
Table of Contents
4 EXECUTIVE SUMMARY
4 Key findings
5 DRUG APPROVALS
6 LABELING
7 DISTRIBUTION
8 FOREIGN DIRECT INVESTMENT
9 INTELLECTUAL PROPERTY ENVIRONMENT
9 Compulsory licensing
10 Counterfeiting
12 BIBLIOGRAPHY
List of Tables
9 Table 1: Indonesia: Compulsory licenses issued in September 2012

Table 1: Indonesia: Compulsory licenses issued in September 2012